Cargando…

Successful treatment of paraganglioma with sorafenib: a case report and brief review of the literature

INTRODUCTION: To date, no effective systemic therapies have been made available for paraganglioma. However, multiple mutations in susceptibility genes have been identified that are potential targets for sorafenib, an oral multitargeted tyrosine-kinase inhibitor. CASE PRESENTATION: We report the case...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yun, Li, Qun, Huang, Wei, Jia, Xinyan, Jiang, Hong, Gao, Yong, Li, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821793/
https://www.ncbi.nlm.nih.gov/pubmed/24235841
http://dx.doi.org/10.2147/OTT.S53813
Descripción
Sumario:INTRODUCTION: To date, no effective systemic therapies have been made available for paraganglioma. However, multiple mutations in susceptibility genes have been identified that are potential targets for sorafenib, an oral multitargeted tyrosine-kinase inhibitor. CASE PRESENTATION: We report the case of a 69-year-old Chinese man with mediastinal paraganglioma that had metastasized to the bone. The paraganglioma responded to sorafenib, a novel multi-tyrosine kinase inhibitor that targets angiogenesis, the Raf-kinase pathway, the platelet-derived growth factor Ret, and c-Kit. The patient was diagnosed as having paraganglioma after biopsy of the mediastinal mass. We first treated the patient with radiotherapy. Then he tolerated an etoposide-and-cisplatin chemotherapy regimen. Subsequently, he received 6 months of maintenance treatment with sorafenib (400 mg twice daily). A dramatic reduction in tumor volume was observed. At present, the patient has achieved a partial response, and his clinical status remains unchanged. CONCLUSION: We suggest that sorafenib should be further investigated in the management of patients with paraganglioma.